(Q44441880)

3 December 2017

0 references

Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial? (English)

1 reference

3 December 2017

Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial? (English)

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

2 January 2024

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

2 January 2024

author name string

David H. Johnson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12748243

2 January 2024

Carlos L. Arteaga

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12748243

2 January 2024

language of work or name

English

0 references

publication date

14 May 2003

1 reference

full work available at URL

3 December 2017

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2003.04.001

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Journal of Clinical Oncology

2 January 2024

published in

1 reference

3 December 2017

21

1 reference

3 December 2017

12

1 reference

3 December 2017

2227-2229

1 reference

Untangling the ErbB signalling network

3 December 2017

2

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

2 January 2024

3

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

2 January 2024

6

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

2 January 2024

7

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

2 January 2024

8

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

2 January 2024

9

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review

2 January 2024

10

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

2 January 2024

11

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

2 January 2024

12

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways

2 January 2024

13

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

2 January 2024

15

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

2 January 2024

17

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype

2 January 2024

19

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

2 January 2024

22

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Women and lung cancer: does oestrogen play a role?

2 January 2024

26

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma.

2 January 2024

27

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Estrogen regulates the synthesis of epidermal growth factor in mouse uterine epithelial cells

2 January 2024

28

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Women who smoke: are women more susceptible to tobacco-induced lung cancer?

2 January 2024

30

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

Influence of unrecognized molecular heterogeneity on randomized clinical trials

2 January 2024

33

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

DNA microarrays in clinical oncology

2 January 2024

34

1 reference

https://api.crossref.org/works/10.1200/JCO.2003.04.001

2 January 2024

Identifiers

1 reference

3 December 2017

1 reference